Skip to main content
Erschienen in: Strahlentherapie und Onkologie 8/2013

01.08.2013 | Original article

Counseling cancer patients on complementary and alternative medicine

Background, theory, and implementation of nationwide counseling facilities

verfasst von: Dr. J. Hübner, K. Muenstedt, R. Muecke, O. Micke, C. Stoll, U.R. Kleeberg, J. Buentzel, G. Dennert, F.J. Prott, On behalf of PRIO (Working group Prevention and Integrative Oncology of the German Cancer Society) and AKTE (Working group Trace Elements of the German Society of Radiooncology (DEGRO)

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Complementary and alternative medicine (CAM) is of high relevance in oncology. Only a minority of professionals feel competent in CAM. Our aim was to provide a strategy for establishing evidence-based counseling on CAM in oncology in the German health system.

Methods

We performed a systematic search of the literature on patient counseling concerning CAM. Of 811 articles identified in this search 51 met our inclusion criteria. Data from these articles were analyzed and adapted to the needs of German patients by a group of experts of the DEGRO (“Deutschen Gesellschaft für Radioonkologie”) and the German Cancer Society. In the next step a strategy about how to integrate evidence-based counseling on CAM at cancer centers and oncological institutions was developed.

Results

First, evidence-based recommendations on CAM counseling were derived. The core of our strategy combines two levels of information provision: level 1 will be oncologists, radiotherapists and other specialists and level 2 oncological CAM experts. The latter group will serve as trainers and backup for complicated or advanced questions and for individual counseling of patients with complex needs. Professionals in level 1 will be offered special training.

Conclusion

Evidence-based counseling on CAM is not only possible but also mandatory in order to meet patient information needs. Our proposal would allow for integrated counseling available at all oncological institutions and guarantee a high quality. Furthermore, provision of information on two different levels allows the effective use of resources (manpower and financing).
Literatur
1.
Zurück zum Zitat Becker-Schiebe M, Mengs U, Schaefer M et al (2011) Topical use of a silymarin-based preparation to prevent radiodermatitis; results of a prospective study in breast cancer patients. Strahlenther Onkol 187(8):485–491PubMedCrossRef Becker-Schiebe M, Mengs U, Schaefer M et al (2011) Topical use of a silymarin-based preparation to prevent radiodermatitis; results of a prospective study in breast cancer patients. Strahlenther Onkol 187(8):485–491PubMedCrossRef
2.
Zurück zum Zitat Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients; the DEGRO-QUIRO trial. Strahlenther Onkol 188(2):113–119PubMedCrossRef Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients; the DEGRO-QUIRO trial. Strahlenther Onkol 188(2):113–119PubMedCrossRef
3.
Zurück zum Zitat Broom A, Tovey P (2008) The role of the internet in cancer patients’ engagement with complementary and alternative treatments. Health (London) 12:139–155 Broom A, Tovey P (2008) The role of the internet in cancer patients’ engagement with complementary and alternative treatments. Health (London) 12:139–155
4.
Zurück zum Zitat Dennert G, Wolf G (2012) Ressourcenorientierte Beratung von Patientinnen und Patienten zur Komplementäronkologie. Ärztliche Psychother Psychosomatische Med 175–180 Dennert G, Wolf G (2012) Ressourcenorientierte Beratung von Patientinnen und Patienten zur Komplementäronkologie. Ärztliche Psychother Psychosomatische Med 175–180
5.
Zurück zum Zitat Eder-Czembirek C, Erovic BM, Czembirek C et al (2010) Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 186(3):143–148PubMedCrossRef Eder-Czembirek C, Erovic BM, Czembirek C et al (2010) Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 186(3):143–148PubMedCrossRef
6.
Zurück zum Zitat Eng J, Ramsum D, Verhoef M et al (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2:212–216PubMedCrossRef Eng J, Ramsum D, Verhoef M et al (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2:212–216PubMedCrossRef
7.
Zurück zum Zitat Ernst E, Resch KL, Mills S et al (1995) Complementary medicine—a definition. Br J Gen Pract 45:506 Ernst E, Resch KL, Mills S et al (1995) Complementary medicine—a definition. Br J Gen Pract 45:506
8.
Zurück zum Zitat Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it‘s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6:313–344PubMedCrossRef Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it‘s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6:313–344PubMedCrossRef
9.
Zurück zum Zitat Frenkel M, Ben-Arye E, Cohen L (2010) Communication in cancer care: discussing complementary and alternative medicine. Integr Cancer Ther 9:177–185PubMedCrossRef Frenkel M, Ben-Arye E, Cohen L (2010) Communication in cancer care: discussing complementary and alternative medicine. Integr Cancer Ther 9:177–185PubMedCrossRef
10.
Zurück zum Zitat Geinitz H, Marten-Mittag B, Schäfer C et al (2012) Patient satisfaction during radiation therapy. Correlates and patient suggestions. Strahlenther Onkol 188(6):492–498PubMedCrossRef Geinitz H, Marten-Mittag B, Schäfer C et al (2012) Patient satisfaction during radiation therapy. Correlates and patient suggestions. Strahlenther Onkol 188(6):492–498PubMedCrossRef
11.
Zurück zum Zitat Hann D, Allen S, Ciambrone D, Shah A (2006) Use of complementary therapies during chemotherapy: Influence of patients’ satisfaction with treatment decision making and the treating oncologist. Integr Cancer Ther 5:224–231PubMedCrossRef Hann D, Allen S, Ciambrone D, Shah A (2006) Use of complementary therapies during chemotherapy: Influence of patients’ satisfaction with treatment decision making and the treating oncologist. Integr Cancer Ther 5:224–231PubMedCrossRef
12.
Zurück zum Zitat Hübner J, Dennert G, Münstedt K (2012) Beratungsangebote zu komplementären und alternative Methoden in der Onkologie. Forum 27:136–139 Hübner J, Dennert G, Münstedt K (2012) Beratungsangebote zu komplementären und alternative Methoden in der Onkologie. Forum 27:136–139
13.
Zurück zum Zitat Maskarinec G, Gotay CC, Tatsumura Y et al (2001) Perceived cancer causes: use of complementary and alternative therapy. Cancer Pract 9:183–190PubMedCrossRef Maskarinec G, Gotay CC, Tatsumura Y et al (2001) Perceived cancer causes: use of complementary and alternative therapy. Cancer Pract 9:183–190PubMedCrossRef
14.
Zurück zum Zitat Micke O, Bruns F, Glatzel M et al (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22–30 Micke O, Bruns F, Glatzel M et al (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22–30
15.
Zurück zum Zitat Molassiotis A, Fernadez-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedCrossRef Molassiotis A, Fernadez-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedCrossRef
16.
Zurück zum Zitat Münstedt K, Harren H, Georgi R von, Hackethal A (2011) Conplementary and alternative medicine: comparison of current knowledge, attitudes and interest among German medical students and doctors. Evid Based Complement Alternat Med. doi: 10.1093/ecam/nen079 Münstedt K, Harren H, Georgi R von, Hackethal A (2011) Conplementary and alternative medicine: comparison of current knowledge, attitudes and interest among German medical students and doctors. Evid Based Complement Alternat Med. doi: 10.1093/ecam/nen079
17.
Zurück zum Zitat Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12:90–98PubMedCrossRef Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12:90–98PubMedCrossRef
18.
Zurück zum Zitat Saxe GA, Madlensky L, Kealey S et al (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the Women’s Healthy Eating and Living Study. Integr Cancer Ther 7:122–129PubMedCrossRef Saxe GA, Madlensky L, Kealey S et al (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the Women’s Healthy Eating and Living Study. Integr Cancer Ther 7:122–129PubMedCrossRef
19.
Zurück zum Zitat Schofield P, Diggens J, Charleson C et al (2010) Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Patient Educ Couns 79:143–151PubMedCrossRef Schofield P, Diggens J, Charleson C et al (2010) Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Patient Educ Couns 79:143–151PubMedCrossRef
20.
Zurück zum Zitat Shelley BM, Sussman AL, Williams RL et al (2009) They don’t ask me so I don’t tell them: patient–clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med 7:139–147PubMedCrossRef Shelley BM, Sussman AL, Williams RL et al (2009) They don’t ask me so I don’t tell them: patient–clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med 7:139–147PubMedCrossRef
21.
Zurück zum Zitat Singh H, Maskarinec G, Shumay DM (2005) Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer. Integr Cancer Ther 4:187–194PubMedCrossRef Singh H, Maskarinec G, Shumay DM (2005) Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer. Integr Cancer Ther 4:187–194PubMedCrossRef
22.
Zurück zum Zitat Snyder JD for the American College of Physicians Ethics, Professionalism, and Human Rights Committee (2012) American College of Physicians Ethics Manual, 6. Edn. http://www.acponline.org/running_practice/ethics/manual/manual6th.htm Accessed: 17 June 2013 Snyder JD for the American College of Physicians Ethics, Professionalism, and Human Rights Committee (2012) American College of Physicians Ethics Manual, 6. Edn. http://​www.​acponline.​org/​running_​practice/​ethics/​manual/​manual6th.​htm Accessed: 17 June 2013
23.
Zurück zum Zitat Verhoef MJ (2009) Complementary therapies for cancer patients: assessing information use and needs. Chronic Dis Can 29:80–85PubMed Verhoef MJ (2009) Complementary therapies for cancer patients: assessing information use and needs. Chronic Dis Can 29:80–85PubMed
Metadaten
Titel
Counseling cancer patients on complementary and alternative medicine
Background, theory, and implementation of nationwide counseling facilities
verfasst von
Dr. J. Hübner
K. Muenstedt
R. Muecke
O. Micke
C. Stoll
U.R. Kleeberg
J. Buentzel
G. Dennert
F.J. Prott
On behalf of PRIO (Working group Prevention and Integrative Oncology of the German Cancer Society) and AKTE (Working group Trace Elements of the German Society of Radiooncology (DEGRO)
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 8/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0392-4

Weitere Artikel der Ausgabe 8/2013

Strahlentherapie und Onkologie 8/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.